Revenue Breakdown
Composition ()
No data
Revenue Streams
PTC Therapeutics Inc (PTCT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sephience, accounting for 55.2% of total sales, equivalent to $124.55M. Other significant revenue streams include Translarna and Emflaza. Understanding this composition is critical for investors evaluating how PTCT navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, PTC Therapeutics Inc maintains a gross margin of 85.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.84%, while the net margin is -1.03%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PTCT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PTCT competes directly with industry leaders such as TGTX and XENE. With a market capitalization of $6.11B, it holds a significant position in the sector. When comparing efficiency, PTCT's gross margin of 85.47% stands against TGTX's 83.65% and XENE's N/A. Such benchmarking helps identify whether PTC Therapeutics Inc is trading at a premium or discount relative to its financial performance.
